WOCKPHARMA Wockhardt Ltd Name Changes Announcement 2023 - Phase 3 Pneumonia Study Wockhardt announces successful completion of pivotal Phase 3 pneumonia study of its macrolide antibiotic Nafithromycin WCK 4873. The study showed that a three-day treatment with Nafithromycin is as effective as a seven-day therapy with Moxifloxacin..Find Corporate Announcements for Press Releases, AGM, Insider Trading & SAST, Results and Corporate Action for Wockhardt Ltd